Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
India · Delayed Price · Currency is INR 4,045.00
+57.80 (1.45%)
Feb 3, 2026, 3:29 PM IST
Torrent Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 122,481 | 115,161 | 107,278 | 96,202 | 85,080 | 80,046 | |
Revenue Growth (YoY) | 9.13% | 7.35% | 11.51% | 13.07% | 6.29% | 0.82% |
Cost of Revenue | 29,779 | 27,759 | 26,862 | 27,352 | 24,420 | 21,464 |
Gross Profit | 92,702 | 87,402 | 80,416 | 68,850 | 60,660 | 58,582 |
Selling, General & Admin | 24,098 | 22,708 | 20,166 | 17,052 | 15,483 | 14,597 |
Other Operating Expenses | 28,674 | 27,484 | 26,573 | 23,377 | 20,865 | 19,184 |
Operating Expenses | 60,821 | 58,141 | 54,693 | 47,449 | 42,967 | 40,354 |
Operating Income | 31,881 | 29,261 | 25,724 | 21,400 | 17,693 | 18,228 |
Interest Expense | -2,164 | -2,514 | -3,526 | -3,322 | -2,529 | -3,508 |
Interest & Investment Income | 201.9 | 201.9 | 114.8 | 147.8 | 71.5 | 50.7 |
Currency Exchange Gain (Loss) | -166.1 | -166.1 | -39.1 | -180.8 | 1,695 | 319.7 |
Other Non Operating Income (Expenses) | -753.1 | 6.9 | 314.4 | 61.1 | 76 | 21.7 |
EBT Excluding Unusual Items | 29,000 | 26,790 | 22,587 | 18,106 | 17,007 | 15,112 |
Merger & Restructuring Charges | -130 | - | - | - | -4,847 | - |
Gain (Loss) on Sale of Investments | 177.3 | 167.3 | 179.9 | 195.1 | 101.4 | 155.8 |
Gain (Loss) on Sale of Assets | 43.4 | 13.4 | -0.2 | 216.2 | - | - |
Asset Writedown | - | - | -129.7 | -45.6 | -2.3 | -4.8 |
Other Unusual Items | -242.1 | -242.1 | 883.8 | - | - | - |
Pretax Income | 28,848 | 26,728 | 23,521 | 18,472 | 12,259 | 15,263 |
Income Tax Expense | 7,446 | 7,616 | 6,957 | 6,019 | 4,487 | 2,744 |
Earnings From Continuing Operations | 21,403 | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 |
Net Income | 21,403 | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 |
Net Income to Common | 21,403 | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 |
Net Income Growth | 18.75% | 15.39% | 33.02% | 60.22% | -37.92% | 22.17% |
Shares Outstanding (Basic) | 338 | 338 | 338 | 338 | 338 | 338 |
Shares Outstanding (Diluted) | 338 | 338 | 338 | 338 | 338 | 338 |
EPS (Basic) | 63.23 | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 |
EPS (Diluted) | 63.23 | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 |
EPS Growth | 18.75% | 15.39% | 33.02% | 60.22% | -37.92% | 22.17% |
Free Cash Flow | 13,582 | 19,732 | 28,333 | 17,942 | 16,004 | 16,702 |
Free Cash Flow Per Share | 40.13 | 58.30 | 83.72 | 53.01 | 47.29 | 49.35 |
Dividend Per Share | - | 32.000 | 28.000 | 22.000 | 16.500 | 17.500 |
Dividend Growth | - | 14.29% | 27.27% | 33.33% | -5.71% | 105.88% |
Gross Margin | 75.69% | 75.89% | 74.96% | 71.57% | 71.30% | 73.19% |
Operating Margin | 26.03% | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% |
Profit Margin | 17.47% | 16.60% | 15.44% | 12.94% | 9.13% | 15.64% |
Free Cash Flow Margin | 11.09% | 17.14% | 26.41% | 18.65% | 18.81% | 20.87% |
EBITDA | 39,478 | 36,758 | 33,249 | 28,026 | 23,823 | 24,291 |
EBITDA Margin | 32.23% | 31.92% | 30.99% | 29.13% | 28.00% | 30.35% |
D&A For EBITDA | 7,598 | 7,498 | 7,526 | 6,626 | 6,130 | 6,063 |
EBIT | 31,881 | 29,261 | 25,724 | 21,400 | 17,693 | 18,228 |
EBIT Margin | 26.03% | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% |
Effective Tax Rate | 25.81% | 28.49% | 29.58% | 32.59% | 36.60% | 17.98% |
Revenue as Reported | 121,994 | 115,394 | 107,858 | 96,653 | 87,046 | 80,615 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.